KNX200 series
Stress adaptation, emotional regulation, nociception (oxytocin‑receptor partial agonists)
PreclinicalActive
Key Facts
Indication
Stress adaptation, emotional regulation, nociception (oxytocin‑receptor partial agonists)
Phase
Preclinical
Status
Active
Company
About Kinoxis Therapeutics
Australian biotech leveraging ALOX15 inhibition for CNS agitation, pain, and substance‑use disorders.
View full company profile